Professional
Added to YB: 2026-02-05
Pitch date: 2026-02-03
CATX [neutral]
Perspective Therapeutics, Inc.
-25.43%
current return
Author Info
Trickle Research is an independent microcap research firm. Visit the website.
Company Info
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States.
Market Cap
N/A
Pitch Price
$5.19
Price Target
15.00 (+288%)
Dividend
N/A
EV/EBITDA
N/A
P/E
-2.65
EV/Sales
238.33
Sector
Biotechnology
Category
growth
Research Update &Target Decrease - Perspective Therapeutics, Inc.
CATX (price target decrease: 12-24mo price target $15 (prev $22.50). VMT-α-NET Phase 1/2 shows promising toxicity but efficacy skepticism persists. Recent $175M raise at $3.79/share provides trial funding but increases dilution. Sanofi's AlphaMedix discontinuation removes competitor. Radiopharm sector out of favor vs 2024 highs.
Read full article (3 min)